[1]
|
Ettinger, D.S., Riely, G.J., Akerley, W., et al. (2013) Thymomas and Thymic Carcinomas: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 11, 562-576. https://doi.org/10.6004/jnccn.2013.0072
|
[2]
|
Scorsetti, M., Leo, F., Trama, A., et al. (2016) Thymoma and Thymic Carcinomas. Critical Reviews in Oncology/Hematology, 99, 332-350. https://doi.org/10.1016/j.critrevonc.2016.01.012
|
[3]
|
Shin, D.W., Cho, J.H., Ha, J. and Jung, K.W. (2022) Trends in Incidence and Survival of Patients with Thymic Epithelial Tumor in a High-Incidence Asian Country: Analysis of the Korean Central Cancer Registry 1999 to 2017. Journal of Thoracic Oncology, 17, 827-837. https://doi.org/10.1016/j.jtho.2022.02.001
|
[4]
|
Ruffini, E., Huang, J., Cilento, V., et al. (2023) The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors. Journal of Thoracic Oncology, 18, 1655-1671. https://doi.org/10.1016/j.jtho.2023.09.002
|
[5]
|
Roden, A.C., Ahmad, U., Cardillo, G., et al. (2022) Thymic Carcinomas—A Concise Multidisciplinary Update on Recent Developments from the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. Journal of Thoracic Oncology, 17, 637-650. https://doi.org/10.1016/j.jtho.2022.01.021
|
[6]
|
Yang, Y., Fan, X.W., Wang, H.B., et al. (2017) Stage IVb Thymic Carcinoma: Patients with Lymph Node Metastases Have Better Prognoses than Those with Hematogenous Metastases. BMC Cancer, 17, Article No. 217. https://doi.org/10.1186/s12885-017-3228-2
|
[7]
|
Hurd, J., Haridas, C., Potter, A., et al. (2022) A National Analysis of Open versus Minimally Invasive Thymectomy for Stage I-III Thymic Carcinoma. European Journal of Cardio-Thoracic Surgery, 62, ezac159. https://doi.org/10.1093/ejcts/ezac159
|
[8]
|
Zhou, M.X., Chen, Y.Y., Huang, C., et al. (2023) Identification of Predictors of Long-Term Survival and Prognostic Outcomes in Thymic Squamous Cell Carcinoma: A Real-World Study. Cancer Medicine, 12, 14025-14036. https://doi.org/10.1002/cam4.6049
|
[9]
|
Zhao, Y., Zhao, H., Hu, D., et al. (2013) Surgical Treatment and Prognosis of Thymic Squamous Cell Carcinoma: A Retrospective Analysis of 105 Cases. The Annals of Thoracic Surgery, 96, 1019-1024. https://doi.org/10.1016/j.athoracsur.2013.04.078
|
[10]
|
Wang, J., Liu, Y., Zhuang, W. and Zhao, Y. (2022) Modified Subcostal Arch Xiphoid Thoracoscopic Expanded Thymectomy for Thymic Carcinoma: A Case Report and Review of Literature. Journal of Cardiothoracic Surgery, 17, Article No. 234. https://doi.org/10.1186/s13019-022-01981-w
|
[11]
|
Zhai, Y., Hui, Z., Gao, Y., et al. (2020) Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma. The Thoracic and Cardiovascular Surgeon, 68, 440-445. https://doi.org/10.1055/s-0039-1688723
|
[12]
|
Wei, M. L., Kang, D., Gu, L., et al. (2013) Chemotherapy for Thymic Carcinoma and Advanced Thymoma in Adults. Cochrane Database of Systematic Reviews, 2013, CD008588. https://doi.org/10.1002/14651858.CD008588.pub2
|
[13]
|
Jin, J. N., Hao, Y., Wang, W. X., et al. (2023) Chemoradiotherapy for Untreated Masaoka-Koga Stage IVB Thymic Carcinoma: A Single-Center Retrospective Study. Strahlentherapie und Onkologie, 199, 313-321. https://doi.org/10.1007/s00066-022-02042-w
|
[14]
|
Chun, S. G.,Rimner, A., Amini, A., et al. (2023) American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncology, 9, 971-980. https://doi.org/10.1001/jamaoncol.2023.1175
|
[15]
|
Maniar, R. and Loehrer Sr, P.J. (2023) Understanding the Landscape of Immunotherapy in Thymic Epithelial Tumors. Cancer, 129, 1162-1172. https://doi.org/10.1002/cncr.34678
|
[16]
|
Kaira, K., Imai, H. and Kagamu, H. (2021) Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. Cancers, 13, Article 1065. https://doi.org/10.3390/cancers13051065
|
[17]
|
Cho, J., Kim, H.S., Ku, B.M., et al. (2019) Pembrolizumab for Patients with Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology, 37, 2162-2170. https://doi.org/10.1200/JCO.2017.77.3184
|
[18]
|
Chen, C., Sun, P. and Long, J. (2022) Robust and Durable Response to First-Line Treatment of Pembrolizumab Combined with Chemotherapy in Two Patients with Metastatic Thymic Squamous Cell Carcinoma: Case Report. Frontiers in Immunology, 13, Article 941092. https://doi.org/10.3389/fimmu.2022.941092
|
[19]
|
Nishii, Y.,Furuhashi, K., Ito, K., et al. (2022) Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy Plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report. Pharmaceuticals, 15, Article 889. https://doi.org/10.3390/ph15070889
|
[20]
|
Kashima, J., Hishima, T., Okuma, Y. et al. (2021) CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets. Frontiers in Oncology, 11, Article 808396. https://doi.org/10.3389/fonc.2021.808396
|
[21]
|
Remon, J., Girard, N., Mazieres, J., et al. (2016) Sunitinib in Patients with Advanced Thymic Malignancies: Cohort from the French RYTHMIC Network. Lung Cancer, 97, 99-104. https://doi.org/10.1016/j.lungcan.2016.04.024
|